Sanofi SA vs VF Corp — how do they compare? Sanofi SA trades at $43.25 (market cap $104.57B), while VF Corp trades at $14.9 (market cap $5.86B). The key difference: Sanofi SA is far larger — about 17.8× VF Corp's market cap, and Sanofi SA pays the higher dividend (5.56%). Which is the better fit depends on your goals.
| SNY | VFC | |
|---|---|---|
Market Cap | $104.57B | $5.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $21.55 |
52-Week Low | $41.33 | $12.21 |
Enterprise Value | $124.48B | $10.14B |
Dividend Yield | 5.56% | 2.42% |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →